Flo sees FY adj EPS $1.00 to $1.10, saw about $1.05 to $1.15

Flo sees FY adj EPS $1.00 to $1.10, saw about $1.05 to $1.15

Altimmune (NASDAQ:ALT) is set to release its Q2 2025 earnings on August 12, with analysts expecting a loss of ($0.30) per share and no revenue [1]. Institutional investors have shown interest, with notable stakes increased by firms like MIRAE ASSET GLOBAL ETFS and Envestnet Asset Management, raising concerns about the stock's performance dynamics.

PVH Corp (NYSE:PVH) reported a 2% year-over-year (YoY) revenue increase for Q1 FY25, reaching $1.984 billion, beating guidance. Non-GAAP EPS was $2.30, while GAAP EPS stood at $0.88 due to a $480 million impairment [3]. The company's EMEA and Americas regions grew, while APAC declined. Tommy Hilfiger rose 3% and Calvin Klein remained flat. The company lowered its FY25 EPS guidance to $10.75–$11.00 due to tariffs.

Cemtrex (NASDAQ:CETX) reported a Q3 GAAP EPS of -$1.78 and revenue of $17M [2]. The company also announced the acquisition of $1 million in Solana and priced 1.25M shares at $1.00 in an underwritten public offering.

Analysts have set new price targets for Altimmune, with William Blair reaffirming a "market perform" rating and HC Wainwright setting a $12.00 target price. Goldman Sachs Group raised shares to a "strong sell" rating, while JMP Securities dropped their target price to $15.00. Wall Street Zen raised shares from a "sell" rating to a "hold" rating [1].

Institutional investors have also shown interest in Altimmune, with Creative Planning, Envestnet Asset Management, Geneos Wealth Management, and MIRAE ASSET GLOBAL ETFS increasing their stakes in the company [1].

References:
[1] https://www.marketbeat.com/instant-alerts/altimmune-alt-to-release-earnings-on-tuesday-2025-08-06/
[2] https://seekingalpha.com/news/4485747-cemtrex-gaap-eps-of-1_78-revenue-of-17m
[3] https://www.fibre2fashion.com/news/apparel-news/us-pvh-q1-revenue-up-2-eps-outlook-trimmed-on-tariffs-303088-newsdetails.htm